Goh Ai Sim
Overview
Explore the profile of Goh Ai Sim including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
5
Citations
48
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Goh Cy C, Teng Keat C, Su Kien C, Ai Sim G
J R Coll Physicians Edinb
. 2022 Sep;
52(2):113-116.
PMID: 36146992
The accelerated development of various vaccines against COVID-19 was a global effort to curb the COVID-19 pandemic. As a result, several unique vaccine-related adverse events were observed. Vaccine-induced immune thrombotic...
2.
Mohamad Ashari Z, Sulong S, Hassan R, Husin A, Ai Sim G, Abdul Wahid S
Asian Pac J Cancer Prev
. 2014 Mar;
15(4):1863-9.
PMID: 24641422
The amplification of telomerase component (TERC) gene could play an important role in generation and treatment of haematological malignancies. This present study was aimed to investigate copy number amplification status...
3.
Elias M, Baba A, Azlan H, Rosline H, Ai Sim G, Padmini M, et al.
Leuk Res
. 2014 Jan;
38(4):454-9.
PMID: 24456693
Discovery of imatinib mesylate (IM) as the targeted BCR-ABL protein tyrosine kinase inhibitor (TKI) has resulted in its use as the frontline therapy for chronic myeloid leukemia (CML) across the...
4.
Elias M, Baba A, Husin A, Sulong S, Hassan R, Ai Sim G, et al.
Biomed Res Int
. 2013 Mar;
2013:129715.
PMID: 23484077
Development of resistance to imatinib mesylate (IM) in chronic myeloid leukemia (CML) patients has emerged as a significant clinical problem. The observation that increased epigenetic silencing of potential tumor suppressor...
5.
Elias M, Baba A, Husin A, Abdullah A, Hassan R, Ai Sim G, et al.
Hematol Rep
. 2013 Jan;
4(4):e23.
PMID: 23355941
Development of resistance to imatinib mesylate (IM) in chronic myeloid leukemia (CML) patients is mediated by different mechanisms that can be classified as BCR-ABL dependent or BCR-ABL independent pathways. BCR-ABL...